Candel Therapeutics
Monday, February 26, 2024
Uris
Oncology
Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage immunotherapy platforms based on novel, genetically modified adenovirus and HSV gene constructs, respectively, and a novel discovery platform called enLIGHTEN™
State
Massachusetts
Country
United States
Website
http://www.candeltx.com
CEO/Top Company Official
Paul Peter Tak, MD, PhD, FMedSci
Lead Product in Development
enLIGHTEN Discovery Platform
CAN-3110
CAN-2409
Development Phase of Primary Product
Phase I
Number Of Unlicensed Products
Multimodal immunotherapies designed from enLIGHTEN Discovery Platform
CAN-3110 (2036, composition of matter)
CAN-2409 (2034, method of use)
12 years data exclusivity
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}